Phase II study of 5‑fluorouracil–leucovorin plus bevacizumab for chemotherapy‑naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602

Adjuvant S-1+DTX for stage III gastric cancer its clinical power based on survival analysis from 2 phase II studies (OGSG0604, OGSG1002)

A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)

A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (HERBIS-4B / OGSG 1106)

An Intergroup phase III trial of Ramucirumab plus Irinotecan in Third or more line Beyond Progression after Ramucirumab for advanced Gastric Cancer (RINDBeRG trial)

Adjuvant S-1+DTX therapy for Stage III gastric cancer: survival analysis of the two phase II trials (OGSG0604, OGSG1002)

測定可能病変を有していない進行再発胃癌を対象としたS-1+DTX 療法とS-1+CDDP 療法のランダム化第Ⅱ相試験(HERBIS-3 / OGSG1104)

A phase II trial of perioperative CapeOx for clinical stage III gastric cancer (OGSG1601)

Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202